News
‘Predicting the future’: Emerging technology may help choose right drug at the right time
Remote patient monitoring using novel technology may make it possible for rheumatologists to choose the “right drug right out of...
PrismRA Test Featured on Fierce Biotech
Originally published by Andrea Park – 02/01/2022 – Source URL Equipped with a blood test capable of predicting an individual’s...
Scipher Medicine announces new clinical utility publication for PrismRA
PrismRA, a first of its kind molecular signature test, predicts non-response to TNFi therapies in patients with rheumatoid arthritis (RA)...
Trellis Rx Furthers Commitment to Advancing the Specialty Pharmacy Practice and Patient Outcomes with Integration of Scipher Medicine PrismRA Precision-Medicine Technology into Clinical Pathways
October 12, 2021, Atlanta, GA and Waltham, MA – Trellis Rx, a leading technology-enabled specialty pharmacy services provider, today announced the...
Ventegra Partners with Scipher Medicine For Patient-Centric Approach To Improve Outcomes and Lower Costs for Rheumatoid Arthritis Care
SEPTEMBER 16, 2021 – WALTHAM, MA Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced...
Molecular Test Further Helps Personalize Rheumatoid Arthritis Care
Author: Bret Stetka, MD Results from a new study suggest that a simple blood test can identify patients who are...
New Partnership Delivers Precision Medicine to Pharmacy Benefits Managers
Specialty drug spending contributes the largest share to rising healthcare costs. To make matters worse, in the case of rheumatoid...
Can a Blood-Based Test Predict TNFi Nonresponse in RA?
Richard Mark Kirkner via Medscape A blood test that uses a patient’s unique genetic signature has shown some ability to...
In RA, New Molecular Signature Test Confirms Who Won’t Respond to Anti-TNF Therapy During Any Point in Therapeutic Journey
Q&A with Erin Connolly-Strong PhD, Head Medical Affairs Scipher Medicine via BiopharmaDive Multiple classes of drugs exist for treating rheumatoid...
Scipher Medicine Increases Patient Access for PrismRA by Expanding Intended Use in Autoimmune Patients
Expanded intended use for the blood test validated in Network-004 study. Now, most rheumatoid arthritis patients can be tested at...